Cholesterol-lowering statin therapy may improve survival in patients with diastolic heart failure (DHF) according to a paper published in Circulation: Journal of the American Heart Association by cardiologists at Wake Forest University Baptist Medical Center.
Currently, there are no treatments shown to improve survival in these patients, who make up about 40 percent of all heart failure cases. Systolic heart failure patients have hearts that don’t pump out enough blood. In DHF, the heart does not fully relax and therefore does not fill properly with blood. The mortality rate is 5 to 8 percent per year.
William C. Little, M.D., head of the cardiology section at Wake Forest Baptist, and his research team found a dramatic difference in the longevity of 137 diastolic heart failure patients followed over a three-year period. The patients were being treated with ACE inhibitors, beta-blockers, calcium blockers or statins – all drugs that are commonly used to treat hypertension or heart-related conditions.
"Some patients in the group had been diagnosed with high cholesterol and placed on statin therapy by their doctors. Others in the group whose cholesterol levels were not as high in general, were not placed on statins," said Little. "But when we followed the patients we found that those who had received statins did dramatically better."
Little and his research team found that during the study period, heart failure patients on statin therapy had a risk of death that was 22 percent lower than the patients receiving the other drugs. Even after adjusting for other factors that could have affected the results, such as hypertension or cardiovascular disease, the heart failure patients on statins still fared better.
Little writes that the improved survival rates in the study might be due to the known beneficial effects of statins in patients with coronary artery disease. Whether diagnosed or not, coronary artery disease is quite common in the elderly population. Too, because diabetes and impaired kidney function are also common in patients with diastolic failure, statins may improve the outcome of these conditions, possibly explaining some of the benefits observed by his team with statins in diastolic heart failure.
"Because the patients were not randomized to which therapy they received, this is not a definitive study," said Little. "However, it certainly suggests that it’s worth looking into using statins to treat patients with diastolic heart failure."
According to previous reports in Circulation as well as the New England Journal of Medicine, diastolic heart failure is a significant healthcare problem. Once hospitalized, patients with diastolic heart failure have a 50 percent chance of rehospitalization within six months. It’s estimated that the cost of treating patients for diastolic heart failure exceeds $3.5 billion a year.
Co-authors of the report include Hidekatsu Fukuta, M.D. international research fellow, Nagoya Medical School, Japan, David C. Sane, M.D., associate professor of medicine, Wake Forest Baptist, and Steffen Brucks, M.D., international research fellow, University of Magdengurg, Germany.
Jim Steele | EurekAlert!
Novel PET imaging agent could help guide therapy for brain diseases
03.04.2018 | Society of Nuclear Medicine and Molecular Imaging
New Computer Architecture: Time Lapse for Dementia Research
29.03.2018 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.
Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.
Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.
Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...
Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.
The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...
Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.
Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...
In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...
13.04.2018 | Event News
12.04.2018 | Event News
09.04.2018 | Event News
20.04.2018 | Health and Medicine
20.04.2018 | Materials Sciences
20.04.2018 | Earth Sciences